Entrar/Registro  
INICIO ENGLISH
 
Acta Pediátrica de México
   
MENÚ

Contenido por año, Vol. y Num.

Índice de este artículo

Información General

Instrucciones para Autores

Mensajes al Editor

Directorio






>Revistas >Acta Pediátrica de México >Año 2013, No. 6


Ruíz-Morales JA, Cruz-Medina CS, Pérez-García M, Campos-Gutiérrez MÁ, del Campo-Martínez M, Olaya-Vargas A
Uso de gammaglobulina en el trasplante de células progenitoras hematopoyéticas y trasplante renal
Acta Pediatr Mex 2013; 34 (6)

Idioma: Español
Referencias bibliográficas: 25
Paginas: 348-352
Archivo PDF: 353.42 Kb.


Texto completo




RESUMEN

La gammaglobulia intravenosa (GGIV) contiene un concentrado de anticuerpos IgG obtenidos de miles de donadores y se ha utilizado como terapia en varias enfermedades, como: inmunodeficiencias primarias, enfermedades autoinmunitarias y enfermedad de Kawasaki. En el área de trasplante se ha usado la GGIV en el tratamiento de infecciones virales, enfermedad injerto contra huésped y en la sensibilización por anticuerpos antidonador. Estos últimos son un factor de riesgo importante para el rechazo agudo mediado por anticuerpos en el trasplante renal y para la falla de injerto durante el trasplante de células progenitoras hematopoyéticas. El uso de GGIV como tratamiento para la sensibilización de los pacientes que se someterán a trasplante renal o de progenitores hematopoyéticos reduce el riesgo de rechazo agudo del injerto.


Palabras clave: GGIV, enfermedad injerto contra huésped, falla de injerto, anticuerpos anti-HLA, rechazo agudo, PRA.


REFERENCIAS

  1. Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulates the immune system? Nat Rev Immunol. 2013;176-189.

  2. Nimmerjahn F. Ravetech JV. The anti-inflammatory activity of IgG: the intravenous paradox. J. Exp. Med. 2007;204:11-15.

  3. Takai T. Roles of Fc receptors in autoimmunity. Nat Rev Immunol. 2002;2:580-592.

  4. Clarkson SB, Bussel JB, Kimberly R P, Valinsky JE, Nachman RL, Unkeless JC. Treatment of refractory immune thrombocytopenic purpura with anti-Fcg-receptor antibody. N Engl J Med. 1986;314:1236-1239.

  5. Samuelson A. Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science. 2001;291:484-486.

  6. Ephrem A. Chamat S, Miguel C, Mouthon L, Caligiuri G, Delignat S, et al. Expansion of CD4+CD25+ regulatory T cells by intravenous inmunoglobulina: critical factor in controlling experimental autoimmune encephalomyelitis. Blood. 2008;111:715-722.

  7. Prasad NK, Papoff G, Zeuner A, Bonnin E, Kazatchkine MD, Ruberti G, Kaveri SV. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the fas apoptotic pathway. J Inmmunol 1998;161:3781-3790.

  8. Le Potter L, Sapir T, Bendaoud B, Youinou P, Shoenfeld Y, Pers JO. Intravenous immunoglobulin and cytokines: focus on tumor necrosis factor family members BAFF and APRIL. Ann NY Acad Sci. 2007;1110:426-432.

  9. Fillipovich AH, Peltier MH, Bechtel MK, Dirksen CL, Strauss SA, Englund JA. Circulating cytomegalovirus (CMV) neutralizing activity in bone marrow transplantation: Comparison of passive immunity in a randomized study of four intravenous IgG products administered to CMV seronegative patients. Blood. 1992;80:2656-2660.

  10. Bass EB, Powe NR, Goodman SN, Graziano SL, Griffiths RI Kickler TS, et al. Efficacy of immune globulin in preventing complications of bone marrow transplantation? A meta-analysis. Bone Marrow Transplant. 1993;28:273-282.

  11. Glowacki LS, Smaill FM. Meta-analysis of immune globulin prophylaxis in transplant recipients for the prevention of symptomatic cytomegalovirus disease. Transplant Proc. 1993;25:1408-1410.

  12. Raanani P, Gafter-Gvili A, Paul M, Leibovici L, Shpilberg O. Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systemic review and meta-analysis. J Clin Oncol. 2009;27:770-781.

  13. Sokos DR, Berger M, Lazarus HMM. Intravenous immunogloblin: appropriate indications and uses in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2002;8:117-130.

  14. Sullivan KM, Kopecky KJ, Jocom J, Fisher L, Buckner CD, Meyers JD, et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med. 1990;323:705-712.

  15. Cordonnier C, Chevret, S. Legrand M, Rafi H, Dhédin N, Lehmann, et al. Should Immunoglobulin therapy be used in allogenic stem-cell transplantation? A randomized, double blind, dose effect, placebo controlled, multicenter trial. Ann Intern Med. 2003;139:8-18.

  16. Feinstein LC, Seidel K, Jocum J, Bowden RA, Anassetti C, Deeg HJ, et al. Reduced dose intravenous immunoglobulin does not decrease transplant- related complications in adults given related donor marrow allografts. Biol Blood Marrow Transplant. 1999;5:369-378.

  17. Gregorie-Gauthier J, Durrie L, Duval A, Fontaine F, Dieng MM, Bourgey M, et al. Use of immunoglobulin in the prevention of GvHD in a xenogeneic NOD/SCID/gc- mouse model. Bone Marrow Transplant. 2012;47:439-450.

  18. Otukesh H, Hoseini R Rahimzadeh N. Treatment update of sensitized pediatric kidney transplant recipients: A review. Exp. Clin Transpl. 2012;10:1-7.

  19. Jordan SC, Tyan D, Stablein D, Mcintosh M, Rose S, Vo A, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J AM Soc Nephrol. 2004;12:3256-3262.

  20. Glotz D, Antoine C, Julia P, Suberbielle-Boissel C, Boudjeltia S, Fraoui R, et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant. 2002;8:758-760.

  21. Montgomery RA, Lonze BE, King KE, Kraus ES, Kucirka LM, Locke JE, et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med. 2011;365:318-326.

  22. Brand A. Doxiadis N, Roelen DL. On the role of HLA antibodies in hematopoietic stem cell transplantation. Tissue Antigens. 2013;81:1-11.

  23. Ciurea SO, de Lima M, Cano P, Korbling M, Giralt S, Shpall EJ, et al. High risk of graft failure in patients with anti-HLA antibodies Undergoing haploidentical stem-cell transplantation. Transplantation. 2009;88:1019-1024.

  24. Cutler C, Kim HT, Sun L, Sese D, Glotzbecker B, Armand P, et al. Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. Blood. 2011;118:6691-6697.

  25. Ciurea SO, Thall F, Wang X, Wang SA, Hu Y, Cano P, et al. Donor-specific anti-HLA abs and graft failure in matched unrelated donor hematopoieticstem cell transplantation. Blood. 2011;118:5957-5964.



>Revistas >Acta Pediátrica de México >Año2013, No. 6
 

· Indice de Publicaciones 
· ligas de Interes 






       
Derechos Resevados 2019